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ABSTRACT: Background. The optimal cumulative dose and timing of
cisplatin administration in various concurrent chemoradiotherapy proto-
cols for nonmetastatic head and neck squamous cell carcinoma (HNSCC)
has not been determined.
Methods. The absolute survival benefit at 5 years of concurrent
chemoradiotherapy protocols versus radiotherapy alone observed in pro-
spective randomized trials reporting on the use of cisplatin monochemo-
therapy for nonnasopharyngeal HNSCC was extracted. In the case of
nonrandomized studies, the outcome results at 2 years were compared
between groups of patients receiving different cumulative cisplatin doses.
Results. Eleven randomized trials and 7 nonrandomized studies were iden-
tified. In 6 definitive radiotherapy phase III trials, a statistically significant
association (p 5 .027) between cumulative cisplatin dose, independent of
the schedule, and overall survival benefit was observed for higher doses.
Conclusion. Results support the conclusion that the cumulative dose of
cisplatin in concurrent chemoradiation protocols for HNSCC has a signifi-
cant positive correlation with survival. VC 2015 Wiley Periodicals, Inc.
Head Neck 38: E2151–E2158, 2016
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INTRODUCTION
Concurrent chemoradiotherapy is the standard treatment
for locally and/or regionally advanced (stage III–IV) head
and neck squamous cell carcinoma (HNSCC), either in a
definitive nonsurgical setting or when used after surgery
in patients with high-risk features in the pathology speci-
men.1 According to the meta-analysis of chemotherapy in
head and neck cancer (MACH-NC), which analyzed
16,485 randomized patients from 87 phase III trials per-
formed between 1965 and 2000, there was an overall sur-
vival benefit of 4.5% at 5 years (hazard ratio
[HR] 5 0.88) when chemotherapy was added to radiation
therapy versus radiotherapy alone. The observed survival
benefit, however, was limited to those patients undergoing
concomitant chemotherapy (50 trials; 9615 patients), with
a benefit of 6.5% at 5 years (HR 5 0.81).2,3
The survival benefit of adding chemotherapy concurrently
to radiation did not differ significantly between groups of
trials with postoperative radiation or definitive radiation
with conventional or altered fractionation, nor was there a
differences between using monochemotherapy and combina-
tion chemotherapy in that respect. However, in the mono-
chemotherapy group of trials, the platinum-based regimens
were found to be significantly more effective than other
types of monochemotherapy. The only statistically signifi-
cant result in the subgroup analysis was a decreasing effect
of chemotherapy on survival with increasing age.3
In HNSCC, cisplatin is currently the most widely used
cytotoxic agent when combined with radiation. According
to the Longitudinal Oncology Registry of Head and Neck
Carcinoma report for the years 2005 to 2010, 70% of
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patients with HNSCC in the United States received a
combination of a cisplatin-based regimen and radiother-
apy; in 49% of patients, single-agent cisplatin was used.4
The rationale for adding cisplatin to radiation therapy is
based on its radiosensitizing properties and a toxicity pro-
file not overlapping with radiotherapy.
The National Comprehensive Cancer Network currently
prefers high-dose single-agent cisplatin as a radiosensi-
tizer for this disease.5 In the majority of prospective
randomized trials, cisplatin 100 mg/m2 given every 3
weeks to reach the targeted cumulative dose of 300 mg/
m2 was used. The importance of a third planned cisplatin
dose of 100 mg/m2 was questioned by Ang,6 who
reviewed the compliance levels within a 3-week regimen
in several published phase III randomized trials. A sub-
stantial fraction of patients from these trials received
fewer than 3 cisplatin doses, and a cumulative dose of
200 mg/m2 was suggested to be sufficient to yield a bene-
ficial antitumor effect.6 Furthermore, the only negative
trial combining single-agent cisplatin and radiotherapy in
MACH-NC used a cumulative dose of 140 mg/m2, sug-
gesting that lowering the cumulative dose of cisplatin
below 200 mg/m2 may be detrimental.3,7,8 These observa-
tions agree with the results of a literature-based meta-
analysis of platinum-based concomitant chemotherapy in
HNSCC reported by Ghi et al.9 They found a comparable
reduction in the risk of death between high-dose cisplatin
(300 mg/m2) and cumulative cisplatin dose <300 mg/m2
plus 5-fluorouracil when compared to radiotherapy alone.
However, there was a marked difference in HRs for death
between cisplatin at an intermediate cumulative dose
(200–225 mg/m2; HR 5 0.68) and at low cumulative dose
(<150 mg/m2; HR 5 1.04) in both cases without 5-
fluorouracil.9
Despite its routine use, the optimal dose and timing of
cisplatin administration in various chemoradiotherapy pro-
tocols has not been elucidated. The purpose of the present
review was to evaluate evidence on the dose-response
relationship for cisplatin when used concurrently with
radiotherapy for the treatment of HNSCC. Because there
are insufficient studies addressing this question, an indi-
rect approach was chosen. The relevant literature on the
use of cisplatin monochemotherapy in concurrent chemo-
radiotherapy protocols for HNSCC was reviewed to com-
pare the survival results after radiotherapy alone and
concurrent cisplatin-based chemoradiotherapy using the
different cisplatin schedules used in the literature. Using
the radiation alone arms as a baseline, the therapeutic
advantages of the varied schedules of cisplatin were cal-
culated in order to quantify the value of differing dose
intensities of concurrent cisplatin.
MATERIALS AND METHODS
Review of the literature
The clinical use of cisplatin was approved by the U.S.
Food and Drug Administration in 1978. Therefore, the
PubMed databases were searched from 1978 to 2014, and
the lists of references in the relevant articles were further
evaluated. The following search terms were used: cispla-
tin, radiotherapy, and head and neck cancer. The results
were then manually filtered by using the following crite-
ria: (1) nonnasopharyngeal head and neck primary tumors
of squamous cell histology; (2) treatment with curative
intent, postoperative or definitive; (3) cisplatin used as
monotherapy concurrently with radiotherapy; (4) numeri-
cal or graphical (Kaplan–Meier plots) presentation of
results on disease control and survival; and (5) reports of
randomized trials and nonrandomized studies published in
the English language. Nonrandomized studies were con-
sidered only if different dose levels of cisplatin were
compared for disease control and survival. For all studies,
the additional criterion was that the same radiotherapy
regimen was used in both treatment arms/groups. In the
case of multiple reports of the same trial/study, the last
one, reporting on the most mature results, was used for
data extraction.
Data extraction
If available, data on locoregional control, event-free
survival, distant metastasis-free survival, and/or overall
survival (OS) were extracted from the selected publica-
tions. Although there were some differences in the end-
point definition of event-free survival across the trials/
studies, the different outcomes were grouped together.
The absolute benefit of concurrent chemoradiotherapy
protocols versus radiotherapy alone observed in prospec-
tive randomized trials was determined as the absolute dif-
ference in survival rates between the 2 treatment groups
at the 5-year timepoint. Absolute differences were always
calculated as chemoradiotherapy minus radiotherapy-
alone arm/group. In the case of nonrandomized studies,
the outcome results at 2 years were compared between
groups of patients receiving different cisplatin doses. Two
types of data were used for this analysis: numerical data
as reported in the text or presented in the tables, and
graphical data in the form of Kaplan–Meier plots. From
articles with only a graphical presentation of the results,
the data points of a given curve were captured using UN-
SCAN-IT version 6.0 Graph Digitizing Software (Silk
Scientific, Orem, UT).
Statistical analysis
If not explicitly reported, the cisplatin dose intensity
used in the selected studies was calculated as the mean
dose administered per patient. The mean dose was calcu-
lated using the data on drug compliance described in the
relevant article. In cases where no information was avail-
able on the dose intensity or compliance of cisplatin, a
planned dose of the drug was used for comparison. The
analysis was performed separately for randomized and
nonrandomized studies, which were further categorized
by type of treatment (ie, postoperative and definitive). In
order to determine the trend in the dose-response relation-
ship of cisplatin when added concurrently to radiotherapy
in prospective randomized trials, a linear regression anal-
ysis was carried out. The SPSS/PC statistical package ver-
sion 18.0 (SPSS, Chicago, IL) was used for this purpose.
RESULTS
Search results
The PubMed search identified 3415 articles. Those
indicating the use of single-agent cisplatin concurrently
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with radiotherapy were reviewed as full-text articles. The
selected articles were classified into 1 of 2 major groups
(ie, randomized studies and nonrandomized studies), and
further categorized based on whether definitive or postop-
erative (chemo)radiotherapy was used. After screening
against the inclusion criteria, 22 articles were found eligi-
ble for further analysis.7,8,10–31 Of these, 17 were reports
on 11 different phase II/III randomized trials, and 7 were
nonrandomized studies.
Evidence from prospective randomized trials
Details of 11 randomized trials reported in 17 articles
are summarized in Table 1.7,8,10–24 Definitive and postop-
erative treatments were used in 8 and 3 trials (reported in
12 and 5 articles), respectively. Four studies were 3-arm
trials (with only 2 arms being reviewed for the purpose of
this analysis).12,13,15–17,21 In 2 trials, the number of
patients recruited was <100,10,11,21 and a phase III clini-
cal testing was carried out in all studies but one.7,8,10–23
Early termination of accrual was reported in 3 of these
trials,10–12,15 and in another 3 trials, there were some
imbalances in the selection of patients, contributing to a
bias, mainly against the combined-therapy arm.7,8,21,24
In the majority of trials, conventional fractionation of
radiotherapy was used, whereas 2 fractions per day were
used in 2 trials.14,18,19 Concurrently with radiation, cispla-
tin was administered daily, weekly, or at 3-week inter-
vals. After reports on drug compliance, the mean
cumulative dose of cisplatin administered was calculated
for 7 trials,10,11,14,16–20,22–24 whereas only a median cumu-
lative cisplatin dose could be estimated for 1 trial.21 Only
3 trials lacked drug compliance data.7,8,12,15
In all but 1 study, the follow-up time was longer than 3
years (range 5 1.8–10.8 years; median 5 5 years). Consid-
ering 4 survival endpoints, the results on locoregional
control were reported in 6 trials, on event-free survival in
8 trials, on distant metastasis-free survival in 7 trials, and
on OS in all evaluated trials. The survival advantage
expressed as the difference in survival rates between the
chemoradiotherapy arm and the radiotherapy-only arm at
5 years are shown in Table 2. When all trials were con-
sidered for linear regression testing, no significant rela-
tionship was found between the cumulative cisplatin dose
and the survival advantage for any of the studied end-
points. In the next step, the analysis was limited to defini-
tive radiotherapy trials in which different tumor sites
were treated, thus excluding the RTOG 9111 larynx pres-
ervation trial.16,17 Furthermore, the Intergroup 1392 trial
was also excluded because of 2 major biases, as under-
powered (premature termination), and without information
on the actually administered cisplatin dose.15 In 6 defini-
tive radiotherapy trials analyzed, a statistically significant
association between cumulative cisplatin dose and
improved OS was noted for higher doses (p 5 .027). As
shown in Figure 1, the relationship is linear with the fol-
lowing model parameters: slope 5 0.221 (95% confidence
interval [CI] 5 0.040–0.401) and r2 5 0.742.
Evidence from nonrandomized studies
In 7 studies, the outcome results after concurrent che-
moradiotherapy using different doses of single-agent cis-
platin were compared and reported accordingly (Table
3).25–31 There were 1 prospective and 6 retrospective
studies reporting on 48 to 264 patients (median 5 94). In
6 studies, chemoradiotherapy was used as definitive treat-
ment, although in 3 of these, a small number were treated
postoperatively.28–30 In 1 study, all patients had postoper-
ative chemoradiotherapy.31 Only conventionally fractio-
nated radiotherapy was used, and cisplatin was
administered on a daily, weekly, or every 3-week basis to
reach the planned doses ranging from 160 mg/m2 to
300 mg/m2. The median follow-up time was 2.2 years
(range 5 1.3–5 years). In individual studies, the outcomes
of patients treated with different dose levels of cisplatin
were compared. When reviewing the outcome results
across the selected studies for statistical significance, no
pattern in the dose-effect relationship could be determined
for cisplatin.
DISCUSSION
Although cisplatin is the most frequently used cytotoxic
agent to enhance the effect of radiation in head and neck
cancer, there are only limited data in the literature
describing the importance of its cumulative dose. Review-
ing the relevant literature, only 11 randomized trials were
found in which radiotherapy was compared with concur-
rent chemoradiotherapy using single-agent cisplatin and
the same radiotherapy regimen in both arms of the trial.
After limiting the analysis to definitive chemoradiother-
apy trials, a significant positive correlation was found
between increased OS and higher cumulative cisplatin
dose. Information on the efficacy of different cisplatin
doses obtained from the nonrandomized studies was
inconclusive.
The dose-effect relationship for cisplatin was suggested
by the MACH-NC, in which only the Intergroup 2382
trial with the lowest cumulative cisplatin dose (140 mg/
m2) of all cisplatin-alone trials showed no survival
advantage in the combined-treatment arm compared to
the radiotherapy-alone arm.3 Important information was
also provided by Ang6 who observed that due to the sig-
nificant toxicity of the cisplatin-radiotherapy combination,
which resulted in the omission of a third planned cisplatin
dose of 100 mg/m2 in a substantial number of patients,
there might be no added benefit beyond the cumulative
cisplatin dose of 200 mg/m2. Moreover, in the RTOG
0129, a phase III randomized trial comparing 2 concur-
rent cisplatin-based chemoradiotherapy regimens, 31% of
patients in the standard fractionated radiotherapy arm
received fewer than 3 prescribed cycles of cisplatin at
100 mg/m2.32 With respect to the number of cisplatin
cycles administered concurrently with standard fractio-
nated radiotherapy, a nonsignificant increased risk of
death was observed when the patients receiving 2 cycles
of cisplatin were compared to those who received 3
cycles (HR 5 1.17; 95% CI 5 0.78–1.76); a more pro-
nounced increase in risk of death was recorded when only
1 cycle of cisplatin was compared to 3 cycles (HR 5 1.52;
95% CI 5 0.80–2.90).33 The results of meta-analysis,
which was published only in abstract form, confirmed
these observations, although the argument is confounded
by the inclusion of trials using 5-fluorouracil in combina-
tion with cisplatin or carboplatin.9 A similar observation
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was reported from the analyses of the NPC 9901 and
NPC 9902 nasopharyngeal trials, in which no benefit was
observed when adding a third cycle of cisplatin at
100 mg/m2.34 A significant association between >5 con-
current weekly cycles of cisplatin at 40 mg/m2 (ie, with a
total dose higher than 200 mg/m2) and better survival, but
not for other cutoff values, such as >4 cycles or >6
cycles, was reported by Loong et al35 in the subgroup
analysis of 141 patients with stage II to III nasopharyn-
geal carcinoma.
In the present study, a significant improvement in OS
was noted with increasing cumulative cisplatin doses
when the analysis was limited to the 6 studies using che-
moradiotherapy as a definitive treatment.7,8,12–14,18,19,21,24
A 2.2% (95% CI 5 0.4% to 4%) absolute benefit in OS
between the combined-treatment arm and the
radiotherapy-only arm was observed for every 10 mg
increase in the cumulative cisplatin dose. In the range of
doses of cisplatin used in these 6 studies (140 mg/m2 to
270 mg/m2), the model was statistically significant
(p 5 .027). Two definitive chemoradiotherapy trials were
excluded from this analysis: the RTOG 9111 larynx pres-
ervation trial, because of the option of salvage surgery for
those who failed chemoradiotherapy, and the prematurely
terminated Intergroup 1392 trial, because of the lack
of information on the actual dose of cisplatin
administered.15–17
With regard to other survival endpoints, no association
between the magnitude of the survival benefit and cumu-
lative cisplatin dose was noted (event-free survival) or
could not be tested because of a small number of avail-
able data points (locoregional control, distant metastasis-
free survival). Thus, based on our analysis, it was not
possible to conclude whether the observed effect of
cumulative cisplatin dose on the OS benefit was associ-
ated with improved locoregional control and/or distant
metastasis-free survival. However, it is of critical impor-
tance to identify the source of the causal relationship
between cumulative cisplatin dose and improvement in
OS, because improved compliance to higher cumulative
drug doses could merely reflect the patient’s better health
and general well-being.35 Information extracted from the
nonrandomized studies was also inconclusive: whereas
Gupta et al26 reported a significant improvement in the
local control and locoregional control with a higher num-
ber of weekly cycles of cisplatin at 30 mg/m2, the inten-
sity of the same chemotherapy regimen did not influence
the outcome, including distant metastasis-free survival, in
the study of Newlin et al.36 Furthermore, Granata et al37
found a significant benefit in 2-year event-free survival
for those patients who received all 3 planned cisplatin
cycles at 100 mg/m2 when compared to the group with
2 cycles of the same chemotherapy, and this benefit
was associated with improved local and regional control
but not distant metastases-free survival.
There were several limitations of our analysis. First of
all, the number of studies included was small with serious
methodological flaws were observed in some of them.
Because the outcome is drastically different between
definitive and postoperative studies, especially given the
current status of human papillomavirus (HPV)-positive
disease, which is mostly a nonsurgical disease, the num-
ber of available studies for statistical analysis was further
reduced. Moreover, at least 2 factors might influence the
net effect of a certain cumulative dose of cisplatin: a frac-
tionation pattern of radiotherapy and drug scheduling. It
is well documented that altered fractionated radiotherapy
is more effective than conventionally fractionated radia-
tion therapy.38 It may be the case that concurrent admin-
istration of a specific dose of cisplatin yields a lesser
benefit when combined with a more effective radiother-
apy regimen. For example, there was no survival advant-
age observed when 2 cycles of cisplatin at 100 mg/m2
and accelerated-fractionation radiotherapy were compared
with 3 cycles of the same chemotherapy and standard-
fractionation radiotherapy in the RTOG 0129 study, sug-
gesting that the effect of more intensive radiotherapy
approximates 1 cycle of cisplatin at 100 mg/m2.32,33
When comparing conventionally fractionated and hyper-
fractionated radiotherapy with and without daily
TABLE 2. Differences in survival rates at 5 years reported in prospective




Survival difference (% at 5 y)
Range Median
All trials (N 5 11)
LRC 6 110 to 116.5 114
EFS 8 13 to 134 110.5
DMFS 7 11 to 129 19
OS 11 0 to 140 113
Definitive RT* (N 5 7)
LRC 2 114 to 114 N.A.
EFS 5 13 to 134 15
DMFS 3 118 to 129 121
OS 7 0 to 140 117
Postoperative RT (N 5 3)
LRC 3 110 to 115 113
EFS 2 111 to 122 N.A.
DMFS 3 11 to 19 14
OS 3 19 to 123 113
Abbreviations: LRC, locoregional control; EFS, event-free survival; DMFS, distant metastasis-
free survival; OS, overall survival; RT, radiotherapy; N.A., not applicable.
* RTOG 9111 larynx preservation trial excluded.
FIGURE 1. Overall survival absolute benefit in relation to a cumu-
lative cisplatin dose in prospective randomized trials on concur-
rent chemoradiotherapy with single-agent cisplatin.
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administration of cisplatin at 6 mg/m2 (the same chemo-
therapy schedule in both combined-treatment arms), Jere-
mic et al13 observed no benefit (either for local and
regional recurrence-free survival or for distant metastasis-
free survival) or only a trend (for OS; p 5 .051) of more
aggressive hyperfractionated chemoradiotherapy over con-
ventionally fractionated chemoradiotherapy. However, the
GORTEC 9902 trial, comparing conventional chemora-
diotherapy versus accelerated radiotherapy plus chemo-
therapy versus highly accelerated radiotherapy alone,
concluded that chemotherapy has a substantial treatment
effect when given concomitantly with radiotherapy and
that acceleration of radiotherapy cannot compensate for
the absence of chemotherapy. They found the most favor-
able outcomes for conventional chemoradiotherapy, sug-
gesting that acceleration of radiotherapy is probably not
beneficial in concurrent chemoradiotherapy schedules.39
With regard to cisplatin scheduling, weekly doses rang-
ing from 30 to 40 mg/m2 or daily administration at 5 to
7 mg/m2 or at 100 mg/m2 administered over several days
have been increasingly used instead of a standard dose of
100 mg/m2 every 21 days. The principle intent of this
modification was to improve treatment compliance in
order to increase the cumulative cisplatin dose and, con-
sequently, the efficacy of combined therapy. Another
rationale for more frequent administration of cisplatin
would be to provide radiosensitizing chemotherapy during
a larger proportion of the course of radiotherapy.40 Retro-
spective comparisons of the efficacy, acute toxicity, and
compliance of weekly and 3-week cisplatin schedules
reported conflicting results.29–31,41–44 However, a model-
ing study by Marcu et al,45 showed that daily administra-
tion of cisplatin with radiotherapy is more efficient than
weekly cisplatin, increasing tumor control by 35% and
6%, respectively, as compared to radiotherapy alone. The
only published study randomizing patients between 2 dif-
ferent cisplatin regimens used concurrently with postoper-
ative radiotherapy for high-risk squamous cell carcinoma
of the oral cavity was reported by Tsan et al.44 Because
of slow recruitment, the study ended after only 55
patients had been recruited. In the standard 3-week cispla-
tin at 100 mg/m2 arm, the mean cumulative dose was
208.5 mg/m2, whereas in the weekly cisplatin at 40 mg/
m2 arm, it was 200.4 mg/m2. After a median follow-up of
12 months, there was no advantage observed in terms of
locoregional control or OS between the 2 arms.44
The relationship between HPV tumor status and cumu-
lative dose of cisplatin is another area of interest. Accord-
ing to recent evidence, this important question relates not
only to oropharyngeal cancer cases but also to other
HNSCC sites.46 Because of well documented survival
advantage of HPV and/or p16 tumor positivity, several
deescalation randomized trials are currently in progress.
However, in none of these trials is the reduced dose of
cisplatin used in the low-intensity arm compared to the
standard-therapy arm.47
Carboplatin, a less toxic derivative of cisplatin, has also
been used as an alternative to cisplatin-based chemoradio-
therapy regimens. Studies suggest that patients may
derive similar benefits with weekly or high doses of car-
boplatin with lesser toxicity, although randomized head-
to-head trials comparing the efficacy cisplatin and carbo-
platin with radiation have not been conducted.48–50 It may
be reasonable to consider the substitution of carboplatin
for cisplatin when toxicities preclude further administra-
tion of cisplatin with radiation. Two studies conducted at
the University of Michigan in organ preservation of the
larynx and oropharynx demonstrated no lack of efficacy
when carboplatin was administered in place of cispla-
tin.51,52 Moreover, the substitution allowed for 3 cycles of
platinum to be administered with radiation, mollifying the
concerns of the reduction in efficacy when <200 mg/m2
of cisplatin could only be delivered.
Our study lends support to the idea that the cumulative
dose of cisplatin in concurrent chemoradiotherapy proto-
cols for HNSCC matters. However, the question of the
optimal dose and schedule is still debatable, as the data
available in the relevant literature are only indirect, often
with a low level of evidence (ie, derived from non-
randomized, mainly retrospective studies). At the
moment, the recommended cumulative dose of cisplatin
that should be administered during radiotherapy seems to
be at least 200 mg/m2, but Figure 1 suggests that the
more cisplatin administered, the higher the benefit. The
importance of the schedule (ie, daily, weekly, or every
3weeks) is unclear from this analysis, as we concentrated
on total dose. There are hints that cisplatin can induce
very late (beyond 5 years) noncancer-related deaths,17,23
and whether this risk is dose-related is unclear. The Japa-
nese JCOG 1008 randomized trial in the postoperative
setting, comparing 2 different chemoradiotherapy proto-
cols with single-agent cisplatin, is ongoing in order to
address the above-mentioned dilemmas. Hopefully, the
outcome of this study might give support to the tendency
to use the lower weekly dose schedules. However, in the
era of intensive research in the field of HNSCC pathoge-
nesis, including molecular mechanisms and targeted drug
design, this question was felt by many to be less of a
priority.
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